Should investors call time on this top growth share?

With shares falling 5%, Paul Summers consider whether it’s time for investors to leave the party.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in premium carbonated mixer supplier Fevertree (LSE: FEVR) dipped over 5% in early trading this morning, despite the company reporting an enviable set of final results to the market.

After more than doubling in price over the last year, has the time now come for growth investors to sell their shares and move on? Let’s take a look at the numbers.

“Another exceptional year”

On the face of it, there appears very little to complain about. 

In 2016, Fevertree’s revenue fizzed 73% to £102.2m with gross profit margins of 55.2% (compared to 51.2% in the previous year). The company recorded excellent growthacross all regions, channels and flavours” with a particularly spirited performance seen in the UK. Here, sales jumped 118% — compared to the 84% acceleration achieved in 2015 — thanks in no small part to superb trading over the festive period. Adjusted EBITDA came in above expectations at £35.8m (a 97% increase on 2015).

While dividends won’t be a priority for nearly all holders, the company also announced a final payment of 4.71p. When combined with its interim payout, this brings the total dividend to 6.25p per share — over double what it was in 2015. As many investors will testify, a rapidly growing but small yield can often be preferable to one that appears overly-generous. The former tends to be indicative of a company in rude health. The latter, on the other hand, may prove unsustainable. Ending the year with £26.9m net cash on its balance sheet, Fevertree looks about as financially sound as businesses come.

All this and the shares fall. How can this be?

As with most star performers, there’s likely to have been some profit-taking going on. That’s perfectly understandable given the company’s wonderful performance over the past couple of years. The decision of co-founder Charles Rolls to move from the position of Executive Chairman to Non-executive Chairman may also have unsettled some.

Possibly the biggest reason however, is that no earnings upgrades were announced. This, when combined with its price-to-earnings (P/E) ratio of 58 for 2017, leaves Fevertree’s shares looking priced to perfection. While its market-leading status and strong branding should give it some protection, I’m concerned by what may happen if and when evidence emerges that rivals — offering cheaper but otherwise similar products — are successfully drawing customers away.

Since expectations tend to be positively correlated with the likelihood of disappointment, I’m left wondering if it may be prudent to take some money off of the table. A superb company? Without doubt. A share worth holding on to in perpetuity? I’m not so sure.

Slower growth, more stability?

Those concerned by the Fevertree’s lack of earnings upgrades but still keen to tap into the relatively resilient drinks industry may wish to move their capital into FTSE 100 constituent, Diageo (LSE: DGE).

With its greater financial clout and larger portfolio of brands (including Baileys, Guinness and Captain Morgan), the £58bn cap is clearly the more defensive choice. Its huge international presence may also be of some comfort to investors concerned by what the triggering of Article 50 could mean for businesses — like Fevertree — that derive the majority of their sales from the UK.

With a P/E of 22 for 2017 and a decently-covered 2.7% yield, those concerned by Fevertree’s vertigo-inducing valuation may find Diageo a more satisfying tipple.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any shares mentioned. The Motley Fool UK has recommended Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »